Filing Flows › BridgeBio Pharma (BBIO) › License and services revenue revenue
BridgeBio Pharma (BBIO) License and services revenue revenue by quarter
BridgeBio Pharma's License and services revenue revenue was $79.3M in Q3 2026 (third quarter 2026), up 14-fold from Q2 2026. Over the last 5 quarters it ranged from $2.9M (Q4 2025) to $79.3M (Q3 2026).
| Quarter | License and services revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $79.3M | 14× | +854% |
| Q2 2026 | $5.8M | +31% | — |
| Q1 2026 | $4.4M | +53% | — |
| Q4 2025 | $2.9M | -65% | — |
| Q3 2025 | $8.3M | — | — |
Q3 2026 at a glance
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is BridgeBio Pharma's License and services revenue revenue?
BridgeBio Pharma's License and services revenue revenue was $79.3M in Q3 2026 (third quarter 2026), up 14-fold from Q2 2026.
How has BridgeBio Pharma's License and services revenue revenue changed?
Over the last 5 quarters it ranged from $2.9M (Q4 2025) to $79.3M (Q3 2026).